<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01496989</url>
  </required_header>
  <id_info>
    <org_study_id>IAVI B004</org_study_id>
    <nct_id>NCT01496989</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Study of HIV-MAG Vaccine +/- IL-12 and Ad35-GRIN/ENV in HIV-uninfected Volunteers</brief_title>
  <official_title>A Phase 1 Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate Safety and Immunogenicity of a Multiantigen HIV (HIV-MAG) pDNA Vaccine With or Without Human IL-12 pDNA GENEVAX® IL-12) and Ad35-GRIN/ENV Vaccine in HIV-Uninfected, Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International AIDS Vaccine Initiative</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Profectus BioSciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ichor Medical Systems Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>International AIDS Vaccine Initiative</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and immunogenicity of
      multiantigen HIV (HIV-MAG) plasmid DNA (pDNA) vaccine co-administered with recombinant human
      IL-12 pDNA (GENEVAX® IL-12) followed or preceded by recombinant Ad35-GRIN/ENV HIV vaccine in
      low-risk for HIV-uninfected healthy adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized, double-blind placebo-controlled trial assessing the safety and
      tolerability of HIV-MAG with or without co-administered GENEVAX® IL-12 given intramuscularly
      by in vivo electroporation (IM/EP) using the Ichor Medical Systems TriGrid Delivery System
      (TDS-IM) followed by Ad35-GRIN/ENV in each of four different regimens. An additional group
      will evaluate the safety and tolerability of Ad35-GRIN/ENV followed by HIV-MAG with
      co-administered GENEVAX® IL-12 given intramuscularly by in vivo electroporation (IM/EP) using
      the Ichor Medical Systems TriGrid Delivery System (TDS-IM).

      Volunteers will be screened up to 42 days before the 1st vaccination and will be followed for
      12 months after the first vaccine administration. It is anticipated that it will take
      approximately 3 months to enrol the study. Approximately 75 volunteers (60 vaccine/15 placebo
      recipients) will be included in the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>13 months approximately</time_frame>
    <description>To evaluate the safety and tolerability of HIV-MAG, GENEVAX® IL-12, and Ad35-GRIN/ENV administered in five heterologous prime-boost regimens.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>12 months</time_frame>
    <description>To assess (qualitative and quantitative) immune responses elicited by the different prime-boost regimens.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Group 1: HIV-MAG followed by Ad35-GRIN/ENV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-MAG (IM/EP) at Months 0,1,2 followed by Ad35-GRIN/ENV (IM) at Month 6. (Vaccine:Placebo = 12/3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: HIV-MAG+GENEVAX® IL-12 followed by Ad35-GRIN/ENV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-MAG + GENEVAX® IL-12 (IM/EP) at Months 0,1,2 followed by Ad35-GRIN/ENV (IM) at Month 6. (Vaccine:Placebo=12/3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: HIV-MAG+GENEVAX® IL-12 followed by Ad35-GRIN/ENV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-MAG + GENEVAX® IL-12 (IM/EP) at Months 0,1,2 followed by Ad35-GRIN/ENV (IM) at Month 6. (Vaccine:Placebo= 12/3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: HIV-MAG+GENEVAX® IL-12 followed by Ad35-GRIN/ENV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-MAG + GENEVAX® IL-12 (IM/EP) at Month 0 followed by Ad35-GRIN/ENV (IM) at Month 4. (Vaccine:Placebo=12/3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5: Ad35-GRIN/ENV followed by HIV-MAG+GENEVAX® IL-12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad35-GRIN/ENV (IM) at Month 0 followed by HIV-MAG + GENEVAX® IL-12 (IM/EP) at Month 4. (Vaccine:Placebo=12/3)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HIV-MAG (3,000mcg)</intervention_name>
    <description>Delivered intramuscularly by in vivo electroporation</description>
    <arm_group_label>Group 1: HIV-MAG followed by Ad35-GRIN/ENV</arm_group_label>
    <arm_group_label>Group 2: HIV-MAG+GENEVAX® IL-12 followed by Ad35-GRIN/ENV</arm_group_label>
    <arm_group_label>Group 3: HIV-MAG+GENEVAX® IL-12 followed by Ad35-GRIN/ENV</arm_group_label>
    <arm_group_label>Group 4: HIV-MAG+GENEVAX® IL-12 followed by Ad35-GRIN/ENV</arm_group_label>
    <arm_group_label>Group 5: Ad35-GRIN/ENV followed by HIV-MAG+GENEVAX® IL-12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GENEVAX® IL-12 (100mcg)</intervention_name>
    <description>Co-administered with HIV-MAG, delivered intramuscularly by in vivo electroporation</description>
    <arm_group_label>Group 2: HIV-MAG+GENEVAX® IL-12 followed by Ad35-GRIN/ENV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GENEVAX® IL-12 (1000mcg)</intervention_name>
    <description>Co-administered with HIV-MAG, delivered intramuscular by in vivo electroporation</description>
    <arm_group_label>Group 3: HIV-MAG+GENEVAX® IL-12 followed by Ad35-GRIN/ENV</arm_group_label>
    <arm_group_label>Group 4: HIV-MAG+GENEVAX® IL-12 followed by Ad35-GRIN/ENV</arm_group_label>
    <arm_group_label>Group 5: Ad35-GRIN/ENV followed by HIV-MAG+GENEVAX® IL-12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad35-GRIN/ENV</intervention_name>
    <description>(2x10^10vp) Delivered intramuscularly by standard needle injection</description>
    <arm_group_label>Group 1: HIV-MAG followed by Ad35-GRIN/ENV</arm_group_label>
    <arm_group_label>Group 2: HIV-MAG+GENEVAX® IL-12 followed by Ad35-GRIN/ENV</arm_group_label>
    <arm_group_label>Group 3: HIV-MAG+GENEVAX® IL-12 followed by Ad35-GRIN/ENV</arm_group_label>
    <arm_group_label>Group 4: HIV-MAG+GENEVAX® IL-12 followed by Ad35-GRIN/ENV</arm_group_label>
    <arm_group_label>Group 5: Ad35-GRIN/ENV followed by HIV-MAG+GENEVAX® IL-12</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy male or female adults,

          -  18 to 50 years of age (21 to 50 years of age for volunteers in Rwanda),

          -  who do not report high-risk behaviour for HIV infection,

          -  who are available for the duration of the trial,

          -  who are willing to undergo HIV testing,

          -  use an effective method of contraception, and

          -  who, in the opinion of the principal investigator or designee, understand the study
             and who provide written informed consent.

        Principal exclusion criteria:

          -  confirmed HIV infection,

          -  pregnancy and lactation,

          -  significant acute or chronic disease,

          -  clinically significant laboratory abnormalities,

          -  recent vaccination or receipt of a blood product,

          -  previous receipt of an HIV vaccine, and

          -  previous severe local or systemic reactions to vaccination or history of severe
             allergic reactions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kenya AIDS Vaccine Initiative, Kangemi</name>
      <address>
        <city>Nairobi</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Projet San Francisco</name>
      <address>
        <city>Kigali</city>
        <country>Rwanda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uganda Virus Research Institute-IAVI</name>
      <address>
        <city>Entebbe</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
    <country>Rwanda</country>
    <country>Uganda</country>
  </location_countries>
  <link>
    <url>http://www.iavi.org</url>
    <description>International AIDS Vaccine Initiative</description>
  </link>
  <link>
    <url>http://www.profectusbiosciences.com/</url>
    <description>Profectus Biosciences, Inc.</description>
  </link>
  <link>
    <url>http://www.ichorms.com/</url>
    <description>Ichor Medical Systems, Inc.</description>
  </link>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2011</study_first_submitted>
  <study_first_submitted_qc>December 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2011</study_first_posted>
  <last_update_submitted>August 30, 2013</last_update_submitted>
  <last_update_submitted_qc>August 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>AIDS</keyword>
  <keyword>HIV vaccine</keyword>
  <keyword>HIV prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Interleukin-12</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

